Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

Daniel H. Fowler, Miriam E. Mossoba, Seth M. Steinberg, David C. Halverson, David Stroncek, Hahn M. Khuu, Frances T. Hakim, Luciano Castiello, Marianna Sabatino, Susan F. Leitman, Jacopo Mariotti, Juan C. Gea-Banacloche, Claude Sportes, Nancy M. Hardy, Dennis D. Hickstein, Steven Z. Pavletic, Scott Rowley, Andre Goy, Michele Donato, Robert KorngoldAndrew Pecora, Bruce L. Levine, Carl H. June, Ronald E. Gress, Michael R. Bishop

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In experimental models, ex vivo induced T-cell rapamycin resistance occurred independent of T helper 1 (Th1)/T helper 2 (Th2) differentiation and yielded allogeneic CD4+ T cells of increased in vivo efficacy that facilitated engraftment and permitted graft-versus-tumor effects while minimizing graft-versus-host disease (GVHD). To translate these findings, we performed a phase 2 multicenter clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of refractory hematologic malignancy. T-Rapa cell products, which expressed a balanced Th2/Th1 phenotype, were administered as a preemptive donor lymphocyte infusion at day 14 post-HCT. After T-Rapa cell infusion, mixed donor/host chimerism rapidly converted, and there was preferential immune reconstitution with donor CD4+ Th2 and Th1 cells relative to regulatory T cells and CD8+ T cells. The cumulative incidence probability of acute GVHD was 20% and 40% at days 100 and 180 post-HCT, respectively. There was no transplant-related mortality. Eighteen of 40 patients (45%) remain in sustained complete remission (range of follow-up: 42-84months). These results demonstrate the safety of this low-intensity transplant approach and the feasibility of subsequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimens. This trial was registered at www.cancer.gov/clinicaltrials as #NCT 00077480.

Original languageEnglish (US)
Pages (from-to)2864-2874
Number of pages11
JournalBlood
Volume121
Issue number15
DOIs
StatePublished - Apr 11 2013
Externally publishedYes

Fingerprint

Th1 Cells
T-cells
Cell Transplantation
Sirolimus
Tissue Donors
Grafts
Clinical Trials
Transplants
Graft vs Host Disease
Cell- and Tissue-Based Therapy
T-Lymphocytes
Lymphocytes
Chimerism
Refractory materials
Tumors
Hematologic Neoplasms
Regulatory T-Lymphocytes
Multicenter Studies
Siblings
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Fowler, D. H., Mossoba, M. E., Steinberg, S. M., Halverson, D. C., Stroncek, D., Khuu, H. M., ... Bishop, M. R. (2013). Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood, 121(15), 2864-2874. https://doi.org/10.1182/blood-2012-08-446872

Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. / Fowler, Daniel H.; Mossoba, Miriam E.; Steinberg, Seth M.; Halverson, David C.; Stroncek, David; Khuu, Hahn M.; Hakim, Frances T.; Castiello, Luciano; Sabatino, Marianna; Leitman, Susan F.; Mariotti, Jacopo; Gea-Banacloche, Juan C.; Sportes, Claude; Hardy, Nancy M.; Hickstein, Dennis D.; Pavletic, Steven Z.; Rowley, Scott; Goy, Andre; Donato, Michele; Korngold, Robert; Pecora, Andrew; Levine, Bruce L.; June, Carl H.; Gress, Ronald E.; Bishop, Michael R.

In: Blood, Vol. 121, No. 15, 11.04.2013, p. 2864-2874.

Research output: Contribution to journalArticle

Fowler, DH, Mossoba, ME, Steinberg, SM, Halverson, DC, Stroncek, D, Khuu, HM, Hakim, FT, Castiello, L, Sabatino, M, Leitman, SF, Mariotti, J, Gea-Banacloche, JC, Sportes, C, Hardy, NM, Hickstein, DD, Pavletic, SZ, Rowley, S, Goy, A, Donato, M, Korngold, R, Pecora, A, Levine, BL, June, CH, Gress, RE & Bishop, MR 2013, 'Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation', Blood, vol. 121, no. 15, pp. 2864-2874. https://doi.org/10.1182/blood-2012-08-446872
Fowler, Daniel H. ; Mossoba, Miriam E. ; Steinberg, Seth M. ; Halverson, David C. ; Stroncek, David ; Khuu, Hahn M. ; Hakim, Frances T. ; Castiello, Luciano ; Sabatino, Marianna ; Leitman, Susan F. ; Mariotti, Jacopo ; Gea-Banacloche, Juan C. ; Sportes, Claude ; Hardy, Nancy M. ; Hickstein, Dennis D. ; Pavletic, Steven Z. ; Rowley, Scott ; Goy, Andre ; Donato, Michele ; Korngold, Robert ; Pecora, Andrew ; Levine, Bruce L. ; June, Carl H. ; Gress, Ronald E. ; Bishop, Michael R. / Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. In: Blood. 2013 ; Vol. 121, No. 15. pp. 2864-2874.
@article{414c923abcba43538e91db1e390c42ce,
title = "Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation",
abstract = "In experimental models, ex vivo induced T-cell rapamycin resistance occurred independent of T helper 1 (Th1)/T helper 2 (Th2) differentiation and yielded allogeneic CD4+ T cells of increased in vivo efficacy that facilitated engraftment and permitted graft-versus-tumor effects while minimizing graft-versus-host disease (GVHD). To translate these findings, we performed a phase 2 multicenter clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of refractory hematologic malignancy. T-Rapa cell products, which expressed a balanced Th2/Th1 phenotype, were administered as a preemptive donor lymphocyte infusion at day 14 post-HCT. After T-Rapa cell infusion, mixed donor/host chimerism rapidly converted, and there was preferential immune reconstitution with donor CD4+ Th2 and Th1 cells relative to regulatory T cells and CD8+ T cells. The cumulative incidence probability of acute GVHD was 20{\%} and 40{\%} at days 100 and 180 post-HCT, respectively. There was no transplant-related mortality. Eighteen of 40 patients (45{\%}) remain in sustained complete remission (range of follow-up: 42-84months). These results demonstrate the safety of this low-intensity transplant approach and the feasibility of subsequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimens. This trial was registered at www.cancer.gov/clinicaltrials as #NCT 00077480.",
author = "Fowler, {Daniel H.} and Mossoba, {Miriam E.} and Steinberg, {Seth M.} and Halverson, {David C.} and David Stroncek and Khuu, {Hahn M.} and Hakim, {Frances T.} and Luciano Castiello and Marianna Sabatino and Leitman, {Susan F.} and Jacopo Mariotti and Gea-Banacloche, {Juan C.} and Claude Sportes and Hardy, {Nancy M.} and Hickstein, {Dennis D.} and Pavletic, {Steven Z.} and Scott Rowley and Andre Goy and Michele Donato and Robert Korngold and Andrew Pecora and Levine, {Bruce L.} and June, {Carl H.} and Gress, {Ronald E.} and Bishop, {Michael R.}",
year = "2013",
month = "4",
day = "11",
doi = "10.1182/blood-2012-08-446872",
language = "English (US)",
volume = "121",
pages = "2864--2874",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation

AU - Fowler, Daniel H.

AU - Mossoba, Miriam E.

AU - Steinberg, Seth M.

AU - Halverson, David C.

AU - Stroncek, David

AU - Khuu, Hahn M.

AU - Hakim, Frances T.

AU - Castiello, Luciano

AU - Sabatino, Marianna

AU - Leitman, Susan F.

AU - Mariotti, Jacopo

AU - Gea-Banacloche, Juan C.

AU - Sportes, Claude

AU - Hardy, Nancy M.

AU - Hickstein, Dennis D.

AU - Pavletic, Steven Z.

AU - Rowley, Scott

AU - Goy, Andre

AU - Donato, Michele

AU - Korngold, Robert

AU - Pecora, Andrew

AU - Levine, Bruce L.

AU - June, Carl H.

AU - Gress, Ronald E.

AU - Bishop, Michael R.

PY - 2013/4/11

Y1 - 2013/4/11

N2 - In experimental models, ex vivo induced T-cell rapamycin resistance occurred independent of T helper 1 (Th1)/T helper 2 (Th2) differentiation and yielded allogeneic CD4+ T cells of increased in vivo efficacy that facilitated engraftment and permitted graft-versus-tumor effects while minimizing graft-versus-host disease (GVHD). To translate these findings, we performed a phase 2 multicenter clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of refractory hematologic malignancy. T-Rapa cell products, which expressed a balanced Th2/Th1 phenotype, were administered as a preemptive donor lymphocyte infusion at day 14 post-HCT. After T-Rapa cell infusion, mixed donor/host chimerism rapidly converted, and there was preferential immune reconstitution with donor CD4+ Th2 and Th1 cells relative to regulatory T cells and CD8+ T cells. The cumulative incidence probability of acute GVHD was 20% and 40% at days 100 and 180 post-HCT, respectively. There was no transplant-related mortality. Eighteen of 40 patients (45%) remain in sustained complete remission (range of follow-up: 42-84months). These results demonstrate the safety of this low-intensity transplant approach and the feasibility of subsequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimens. This trial was registered at www.cancer.gov/clinicaltrials as #NCT 00077480.

AB - In experimental models, ex vivo induced T-cell rapamycin resistance occurred independent of T helper 1 (Th1)/T helper 2 (Th2) differentiation and yielded allogeneic CD4+ T cells of increased in vivo efficacy that facilitated engraftment and permitted graft-versus-tumor effects while minimizing graft-versus-host disease (GVHD). To translate these findings, we performed a phase 2 multicenter clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after allogeneic-matched sibling donor hematopoietic cell transplantation (HCT) for therapy of refractory hematologic malignancy. T-Rapa cell products, which expressed a balanced Th2/Th1 phenotype, were administered as a preemptive donor lymphocyte infusion at day 14 post-HCT. After T-Rapa cell infusion, mixed donor/host chimerism rapidly converted, and there was preferential immune reconstitution with donor CD4+ Th2 and Th1 cells relative to regulatory T cells and CD8+ T cells. The cumulative incidence probability of acute GVHD was 20% and 40% at days 100 and 180 post-HCT, respectively. There was no transplant-related mortality. Eighteen of 40 patients (45%) remain in sustained complete remission (range of follow-up: 42-84months). These results demonstrate the safety of this low-intensity transplant approach and the feasibility of subsequent randomized studies to compare T-Rapa cell-based therapy with standard transplantation regimens. This trial was registered at www.cancer.gov/clinicaltrials as #NCT 00077480.

UR - http://www.scopus.com/inward/record.url?scp=84879448457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879448457&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-08-446872

DO - 10.1182/blood-2012-08-446872

M3 - Article

C2 - 23426943

AN - SCOPUS:84879448457

VL - 121

SP - 2864

EP - 2874

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -